Hemodynamic profile of neonates with neonatal encephalopathy treated with sildenafil in addition to therapeutic hypothermia
Abstract
Abstract Objective: To evaluate sildenafil’s effects on cardiac function and hemodynamic stability in neonates with moderate-to-severe hypoxic-ischemic encephalopathy (HIE) treated with therapeutic hypothermia (TH). Study Design: Two phase Ib trials (SANE-01/02; NCT02812433, NCT04169191) enrolled neonates with MRI-confirmed brain injury receiving sildenafil (n=20) or placebo (n=4) enterally (2.0–3.0 mg/kg q12h × 14 doses). Targeted echocardiography, speckle-tracking, and biomarkers were measured on days 2–10. Results: Sildenafil improved left and right ventricular outputs (p=0.02; pConclusion: Sildenafil was well tolerated and improved cardiovascular function, supporting its potential as an adjunctive therapy in HIE.
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.